Abstract Number: PB0262
Meeting: ISTH 2021 Congress
Background: Covid-19 infection is associated with a widespread global activation of coagulation and affected patients are at an increased risk of thrombosis.
Aims: Heparin therapy is effective in various setting in preventing thromboembolic complications and aim of this study was to assess heparin response in COVID-19 patients through anti-FXa test.
Methods: In 52 patients, M:F ratio 59:41, median age 59 years old, admitted in different intensity of care units of our hospital, treated with different regimens of heparin (100 U/kg every 24 hours in low intensity care, 70U/kg every 12 hours in intermediate intensity care and 100 U/kg every 12 hours in intensive care unit), anti-FXa levels were measured immediately before and 3 hours after subcutaneous enoxaparin administration. On the same samples thrombin generation tests were performed.
Results: Patients treated with 100U/kg every 24 hours and 70 U/kg every 12 hours had median anti-FXa basal levels in the prophylactic range, respectively 0.18 and 0.22 U/ml, while patients treated with 100U/kg every 12 hours were in the anticoagulant range (0.37 U/ml). Despite heparin therapy thrombin generation was elevated in COVID-19 patients, indicating a high level of coagulation activation.
Conclusions: In conclusion we demonstrated that the biological response to enoxaparin in COVID-19 patients is in the expected range using anti-FXa assay and patients are not resistant to heparin therapy.
To cite this abstract in AMA style:Artoni A, De Zan V, Boscarino M, Novembrino C, Scalambrino E, Aliberti S, Panigada M, Martinelli I, Tripodi A, Peyvandi F. Anticoagulant Response to Tailored Low Molecular Weight Heparin Regimens in Patients with COVID-19 Infection [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/anticoagulant-response-to-tailored-low-molecular-weight-heparin-regimens-in-patients-with-covid-19-infection/. Accessed August 9, 2022.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/anticoagulant-response-to-tailored-low-molecular-weight-heparin-regimens-in-patients-with-covid-19-infection/